Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients

By  

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 3923-3931

Blackwell Publishing

Access to resources Recommend Favorite

Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

By Alva Ajjai  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 749-757

Springer Publishing Company

Access to resources Recommend Favorite

Bicalutamide: an alternative to castration in prostate cancer?

By  

Inpharma, Vol. 1, Iss. 1554, 2006-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer

By Okamoto Isamu   Miyazaki Masaki   Morinaga Ryotaro   Kaneda Hiroyasu   Ueda Shinya   Hasegawa Yoshikazu   Satoh Taroh   Kawada Akira   Fukuoka Masahiro   Fukino Koichi   Tanigawa Takahiko   Nakagawa Kazuhiko  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 844-853

Springer Publishing Company

Access to resources Recommend Favorite

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer

By Ganesan Prasanth   Piha-Paul Sarina   Naing Aung   Falchook Gerald   Wheler Jennifer   Fu Siqing   Hong David   Kurzrock Razelle   Janku Filip   Laday Shell   Bedikian Agop   Kies Merrill   Wolff Robert   Tsimberidou Apostolia  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 279-286

Springer Publishing Company

Access to resources Recommend Favorite